The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap in combination with an older cancer drug, faslodex, as a treatment option for patients with the most common type of breast cancer, specifically the HR-positive/HER2-negative subtype.
Truqap, chemically known as capivasertib, is an AKT inhibitor that targets the AKT1 gene mutation responsible for tumor growth and proliferation. The drug showed promise in a late-stage study by extending the time patients with gene-altered tumors lived without their disease worsening by 7.3 months. Breast cancer is the most common cancer diagnosed among women in the United States, and treatment options are crucial in improving patient outcomes.